Core Viewpoint - The stock price of药捷安康-B (02617.HK) experienced extreme volatility today, with a peak increase of over 60% in the morning, followed by a sharp decline of more than 60% in the afternoon, leading to significant market capitalization loss. Group 1: Stock Performance - In the morning, the stock price reached a high of 679.5 HKD per share, with market capitalization nearing 270 billion HKD [1][2] - By the afternoon, the stock price plummeted to a low of 165 HKD per share, resulting in a drop of 60.24% [2] - The closing price was reported at 192 HKD per share, reflecting a decrease of 53.73% and a market capitalization of 76.2 billion HKD [2] Group 2: Company Announcements - The company issued a statement acknowledging the unusual stock price and trading volume fluctuations, stating that it was unaware of any reasons for these changes [4] - The board confirmed that there were no significant changes in the company's business operations or financial status [4] Group 3: Historical Context -药捷安康 was listed on the Hong Kong Stock Exchange on June 23, with an initial price of 13.15 HKD per share, and has seen its stock price increase significantly since then [5] - The stock price surged nearly 500% from September 10 to September 15, with a peak price of 679.5 HKD representing a 5067% increase from the initial listing price [6] Group 4: Financial Performance - The company remains in a loss position, with a pre-tax loss of 123 million HKD for the first half of the year, an improvement from a loss of 160 million HKD in the same period last year [6] - Other income and revenue decreased by 65.1%, from 10.4 million HKD to 3.6 million HKD, primarily due to reduced bank interest and government subsidies [6] - Research and development costs decreased by 30.9% to 98.43 million HKD, attributed to lower clinical trial expenses for the TT-00420 project [6]
鼎锋优配融资证券2000亿大绞杀!药捷安康股价大跌，暴涨超50倍